Skip to content

Preferred Stock at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$0
Biogen logo
BiogenBIIB
$0
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$0
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$0
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$0
Cytokinetics logo
CytokineticsCYTK
$0

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$872.26M+135%
Enterprise value$595.83M+223%
P/S107.8×-9.9×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Solid Biosciences Inc.’s 10-K, filed March 13, 2019, on SEC EDGAR. View the filing →

Questions, answered.

What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.